What are Cometriq and Cabometyx, and what do they treat?
Cometriq is a brand of cabozantinib used for medullary thyroid cancer (MTC) and is typically referenced in that context.
Cabometyx is also cabozantinib, and it is widely used for additional cancers beyond MTC, including advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), depending on the specific regimen and region.
In practice, both brands use the same active ingredient (cabozantinib), but they are approved and prescribed for different cancer indications.
Are they the same drug? What changes between the brands?
Yes—both Cometriq and Cabometyx are cabozantinib products, so the core medicine is the same. The meaningful differences are usually tied to:
- Which cancer indications each brand is approved for
- The formulation and dosing schedule used for those indications
- How the product is packaged and billed in routine care
Because cabozantinib is the same drug class, the main side-effect profile overlaps heavily between the two.
How do side effects compare?
Because both are cabozantinib, the side-effect profile generally matches across brands. Patients commonly ask about:
- Diarrhea, nausea, decreased appetite
- Fatigue
- Hand-foot skin reactions (palmar-plantar erythrodysesthesia)
- Hypertension
- Low blood counts and liver enzyme changes
- Protein in the urine and clotting/bleeding risks
- Mouth sores
Which side effects show up most and how severe they get can still vary by dose and the particular cancer being treated, since regimens may differ.
How do the dosing regimens differ in real-world use?
They can differ based on the indication and the approved labeling for that brand. Even with the same active ingredient, clinicians often use different dose schedules (and sometimes supportive meds) depending on whether the cabozantinib is being used for MTC (Cometriq context) or other cancers (Cabometyx context).
If you tell me which cancer you’re asking about (or the exact prescription you have), I can help map the brand to the typical labeled regimen for that setting.
Which one is “better” for a specific cancer?
For a given patient, the “better” option is usually the one that matches the approved indication and dosing used for that cancer type. Since they share the same active drug, choice often comes down to:
- The cancer type and line of therapy
- Insurance coverage and prior authorization
- Whether the clinician is following an approved regimen for that brand’s indication
What about patents and brand availability?
Branding can affect availability and pricing, even when the active ingredient is the same. If you’re researching cost or exclusivity, DrugPatentWatch.com tracks patent and exclusivity details that may explain differences in access over time (including for cabozantinib products). You can check current status here: https://www.drugpatentwatch.com/
Quick bottom line
Cometriq and Cabometyx are both cabozantinib products, so they are closely related in mechanism and likely share many side effects. The practical differences are mainly the approved cancer indications, dosing regimens for those indications, and how each is sold/covered.
Sources
- https://www.drugpatentwatch.com/